Schedule H1 Drug List 2026: Indian Pharmacy Guide

Why Schedule H1 compliance is no longer optional in practice

Every Indian pharmacist has heard the phrase "maintain the H1 register." It has been the standard refrain since 2013 when Schedule H1 was introduced through an amendment to the Drugs and Cosmetics Rules, 1945 (under the parent Drugs and Cosmetics Act, 1940). But something shifted between 2024 and 2026 that changed the enforcement landscape fundamentally: CDSCO and state drug controllers stopped treating H1 register maintenance as a suggestion they would warn you about and started treating it as a hard compliance boundary with real consequences.

The trigger was antimicrobial resistance data. India's National Action Plan on Antimicrobial Resistance, updated in 2024, explicitly identified over-the-counter antibiotic dispensing as a primary driver of resistance patterns that are now showing up in hospital ICUs as untreatable infections. The regulatory response was predictable: tighter enforcement of the mechanism that was specifically designed to control this problem. That mechanism is Schedule H1 tracking. If you are a pharmacy owner or pharmacist dispensing H1 drugs without meticulous documentation, the risk profile in 2026 is materially different from what it was even two years ago.

What is Schedule H1 and how does it differ from Schedule H

Schedule H covers prescription-only medicines broadly. Schedule H1 is a subset carved out in 2013 that imposes additional documentation obligations beyond the standard prescription requirement. The distinction matters because a Schedule H drug requires a prescription to dispense but does not require a dedicated register entry for each sale. A Schedule H1 drug requires both.

The rationale for this additional layer was targeted: the drugs placed in Schedule H1 were those most frequently dispensed without valid prescriptions across Indian retail pharmacies, particularly antibiotics contributing to antimicrobial resistance, certain habit-forming substances prone to misuse, and anti-tuberculosis drugs whose unsupervised use undermines RNTCP treatment protocols.

The practical difference for your pharmacy:

• Schedule H drugs: Prescription required. Sale recorded in normal billing. No separate register mandated.
• Schedule H1 drugs: Prescription required. Sale must be recorded in a dedicated H1 register with specific fields. Prescription must be retained. Monthly summaries must be maintained. Records kept for three years minimum.

Failing to maintain the register does not just attract a warning. Under the Drugs and Cosmetics Act, 1940 (Section 18 read with Section 27), non-compliance with scheduled drug dispensing requirements can result in penalties up to one lakh rupees for first offences and imprisonment up to two years for subsequent violations.

The Schedule H1 drug list: 2026 reference

The Schedule H1 list is notified through Gazette of India notifications and has been incrementally updated since its 2013 introduction. The following categories and specific drugs constitute the current H1 list that every pharmacy must track.

Antibiotics and anti-infectives

This is the largest category and the primary reason H1 exists:

Anti-tuberculosis drugs

Individual formulations (not fixed-dose DOTS combinations) are H1-listed:

• Rifampicin (individual formulation)
• Isoniazid (individual formulation)
• Ethambutol (individual formulation)
• Pyrazinamide (individual formulation)

The critical distinction: fixed-dose combinations supplied through the RNTCP/NTEP programme are handled differently. It is the individual-sale formulations purchased from distributors and dispensed on private prescriptions that require H1 register entries.

Habit-forming and psychotropic substances on H1

Note: Higher-strength formulations of Alprazolam and all Diazepam above certain thresholds may fall under Schedule X with NDPS Act implications. Know where the H1/X boundary lies for every psychotropic you stock.

Anti-malarials

• Artesunate (combinations)
• Artemether + Lumefantrine (combination)

Other notable H1 drugs

• Ketoconazole (systemic formulation, not topical)
• Fluconazole (certain formulations)
• Misoprostol
• Letrozole (added due to off-label misuse concerns)

The full gazette notification should be verified annually through the CDSCO website (cdsco.gov.in) as additions and reclassifications occur through separate notifications. Do not rely on a static list from any source, including this guide. Cross-check.

Rule 65(15A): what the register must contain

Every sale of a Schedule H1 drug must be recorded with the following fields. Missing any one of these during an inspection is a documentable finding:

• Date of sale -- the actual date, not a backfilled date
• Name of the drug -- both brand name AND generic name (INN). Recording only "Augmentin" without "Amoxicillin 500mg + Potassium Clavulanate 125mg" is non-compliant
• Quantity dispensed -- strip count, bottle count, or unit count as applicable
• Batch number -- the specific batch from which the drug was physically dispensed, not the most recently received batch
• Patient name and address -- full name, not initials; address should be reasonably complete
• Prescribing doctor's name -- full name as it appears on the prescription
• Doctor's registration number -- State Medical Council or NMC registration number
• Date of prescription -- to verify the prescription is current

Records must be retained for a minimum of three years from the date of the last entry in the register. The register may be maintained in physical or digital form, but digital registers must be tamper-proof (preventing retroactive edits without an audit trail) and printable on demand in register format.

**Pro tip:** Digital record-keeping is not just acceptable under Rule 65(15A) -- it is increasingly preferred by Drug Inspectors because it eliminates the ambiguity of handwriting, produces consistent formatting, and enables instant search during audits. Tools like [ShelfLifePro for Pharmacies](/pharmacy/) generate compliant H1 register entries automatically at the point of billing, linking the correct batch number, generic name, and prescription details without requiring manual entry. This eliminates the two most common compliance failures: missing batch numbers and end-of-day backfilling.

Storage requirements for Schedule H1 drugs

Beyond register maintenance, physical storage of H1 drugs must meet specific standards under Schedule N of the Drugs and Cosmetics Rules:

• Separate, clearly labelled section within your Schedule H storage area. H1 drugs must be visually distinguishable from general Schedule H stock. A labelled shelf, rack section, or drawer is the minimum. Inspectors should be able to identify your H1 section within seconds of entering the dispensing area.
• Temperature control as specified on each product's label. Most H1 antibiotics require storage below 25 degrees Celsius. In Indian summers, this means air conditioning during operating hours is effectively mandatory, not optional.
• Humidity control -- particularly critical for capsule formulations (Azithromycin, Cefixime capsules) which are sensitive to moisture. Humidity above 60% can degrade product integrity.
• Light protection -- several fluoroquinolones are light-sensitive. Avoid direct sunlight exposure on shelving.
• FEFO arrangement -- First Expiry, First Out. Batches with the nearest expiry date must be positioned for dispensing first. An inspector who pulls a strip from the front of your shelf and finds it has a later expiry than the strip behind it has a storage violation to document.

Cold chain H1 drugs

Certain H1 drugs or their formulations require 2-8 degrees Celsius storage (injectable antibiotics, certain reconstituted suspensions). For these:

• Dedicated pharmaceutical-grade refrigerator (not a domestic unit)
• Temperature log maintained twice daily at minimum
• Backup power arrangement documented
• Temperature excursion protocol in place

CDSCO digital compliance: where things are heading

The Central Drugs Standard Control Organisation has been steadily pushing pharmacy operations toward digital documentation. The DAVA (Drug Authentication and Verification Application) portal, expanded state-level digital drug tracking mandates, and SUGAM portal reforms all point to one trajectory: paper registers are a transitional state, not the end state.

Several state drug controllers -- notably Tamil Nadu (TNMDA), Karnataka, and Maharashtra -- have already implemented or are piloting systems that expect pharmacies to submit H1 dispensing data electronically. Even where electronic submission is not yet mandated, inspectors increasingly ask whether your records are digitally maintained and searchable.

What "tamper-proof digital register" means in practice:

• Immutable entries -- once a sale is recorded, the original entry cannot be altered. Corrections must create a new audit trail entry that preserves the original.
• Timestamp integrity -- entries must be timestamped at the point of sale, not backdated.
• Batch-level linkage -- the register entry must connect to the actual inventory deduction from a specific batch.
• Prescription linking -- storing a scanned or photographed copy of the prescription alongside the digital register entry creates the strongest compliance evidence.
• Print-on-demand -- the system must produce the register in standard format (not a raw Excel export) that matches what inspectors expect to review.

What Drug Inspectors check during an H1 audit

Based on enforcement patterns across multiple states, here is the typical H1 audit sequence:

Phase 1: Visual inspection (first 10 minutes)

• Is the drug license current and displayed?
• Is the pharmacist named on the license physically present?
• Are Schedule H and H1 drugs stored separately from OTC products?
• Is the H1 section clearly labelled?
• Are any visibly expired products on the H1 shelf?

Phase 2: Register review (20-30 minutes)

This is the core of the H1 inspection:

• Select 5-10 random entries from the past 60 days
• Verify every mandatory column is filled for each entry
• Cross-reference 2-3 entries against the POS billing records -- does the sale appear in both?
• Check batch numbers in the register against current shelf stock -- do the numbers reconcile?
• Look for patterns indicating backfilling: identical timestamps for multiple entries, uniform handwriting suggesting single-sitting completion, gaps that align with weekends or holidays

Phase 3: Reconciliation (15-20 minutes)

The inspector selects 2-3 high-volume H1 drugs and performs a manual reconciliation:

• Total purchased (from purchase invoices) minus total dispensed (from register) minus returns/destruction (from Form 29) should equal current physical stock
• A discrepancy triggers an automatic escalation. For H1 drugs, unlike regular Schedule H, there is very little tolerance for "approximate" reconciliation

Phase 4: Prescription verification (10 minutes)

• Are original prescriptions (or copies) retained for H1 sales?
• Do prescription dates fall within a reasonable dispensing window?
• Are prescribing doctors identifiable through their registration numbers?
• Any prescriptions from unlicensed practitioners?

Escalation framework

The response to findings follows a predictable scale:

• Minor gaps (1-2 entries with missing fields): Verbal warning with correction guidance
• Systematic gaps (pattern of missing batch numbers, incomplete doctor details): Written observation with a 30-day correction timeline
• Material non-compliance (no register, register more than 30 days behind, expired H1 stock on shelf): Show-cause notice under Rule 65
• Serious violations (H1 drugs dispensed without prescriptions, register fabrication, stock discrepancies suggesting diversion): Prosecution recommendation; potential license suspension

Compliance checklist: your 15-point H1 audit preparation

Use this before your next license renewal or when you hear inspections are happening in your area:

Register and documentation

• [ ] H1 register is current with entries for every H1 sale in the past 90 days
• [ ] Every entry includes both brand name AND generic name
• [ ] Batch numbers are recorded for every entry and match actual dispensed stock
• [ ] Doctor registration numbers (NMC/State Medical Council) are recorded for every entry
• [ ] Patient name and address are complete (not initials or abbreviations)
• [ ] Original prescriptions or copies are retained and accessible for the past 3 years
• [ ] Register is tamper-proof -- no correction fluid, no pencil entries, no erased entries
• [ ] Digital register (if used) produces print-on-demand output in standard register format

Physical storage

• [ ] H1 drugs are in a clearly labelled, separate section within Schedule H storage
• [ ] FEFO arrangement is maintained -- earliest expiry at the front
• [ ] No expired H1 drugs on any shelf (check every batch, not just the front strip)
• [ ] Temperature-sensitive H1 drugs are in appropriate cold storage with daily logs
• [ ] Room temperature is documented and maintained below 25 degrees Celsius

Reconciliation readiness

• [ ] Batch-wise stock reconciliation is current for all high-volume H1 drugs
• [ ] Form 29 destruction records exist for any H1 drugs disposed of due to expiry or damage

If you cannot check every box on this list today, you have identified your compliance gaps. Fix them before an inspector does.

The real cost of non-compliance versus compliance

The arithmetic here is unambiguous.

Cost of compliance:

• Physical register: INR 200-500
• Digital H1 register system: INR 5,000-15,000/year (or free if your billing software supports it natively)
• Staff time at 2-3 minutes per H1 sale, assuming 20 H1 sales/day: approximately 45-60 minutes daily

Cost of non-compliance:

• Show-cause notice legal response: INR 5,000-25,000 per instance
• First-offence penalty under Rule 65: up to INR 1,00,000
• License suspension: INR 20,000-50,000/day in lost revenue for a mid-size pharmacy
• License cancellation: loss of the entire business
• Criminal prosecution for serious violations: legal fees, reputation damage, potential imprisonment

There is no version of this calculation where cutting corners on H1 compliance is economically rational. The compliance cost is bounded and predictable. The non-compliance cost is unbounded and catastrophic.

Building a system that stays compliant without heroic effort

The pharmacies that consistently pass H1 inspections are not the ones with the most dedicated staff or the most rigorous manual processes. They are the ones where the system makes compliance the default rather than an additional task layered on top of normal operations.

What this means practically:

• Billing and H1 register should be the same action. If your staff has to complete a sale in the POS and then separately update a register, the register will fall behind. When the H1 entry is generated automatically from the billing transaction, with the correct batch number pulled from FEFO-managed inventory, compliance is a byproduct of doing business rather than an additional obligation.
• Batch-level inventory tracking eliminates reconciliation failures. The most common H1 audit finding is a stock count that does not match register records. This happens because the register records one batch while the staff physically dispensed from a different batch. ShelfLifePro tracks inventory at the batch level and defaults to FEFO dispensing, which means the register always reflects what was actually sold.
• Prescription digitisation closes the evidence chain. Photographing the prescription at the point of sale and linking it to the register entry means you can produce the complete audit trail -- prescription, register entry, batch deduction -- in seconds during an inspection rather than searching through paper files.

Where enforcement is heading

Schedule H1 compliance in 2026 is not a paperwork exercise. It is a regulatory boundary that Indian pharmacies must operate within to maintain their licenses, avoid financial penalties, and contribute to the national effort against antimicrobial resistance. The drug list is well-defined, the register requirements are specific, and the enforcement machinery is more active than it has ever been.

The standard is the same whether you use a physical register maintained with discipline or a digital system like ShelfLifePro that automates the process: every H1 drug, every sale, every batch, every prescription, fully documented and instantly auditable. The systems that survive inspections are the ones where H1 tracking is built into the billing workflow, not maintained as a separate compliance exercise.

This guide references the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945 (as amended), Rule 65(15A), CDSCO guidelines, and state drug control enforcement patterns. Drug scheduling is updated through Gazette of India notifications. Always verify the current H1 list at cdsco.gov.in and consult your State Drug Controller for state-specific requirements.